Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 8/20 | 0.45 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.44 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.44 |
| ▸ | ITGAL | P20701 | 1/20 | 0.44 |
| ▸ | TYK2 | P29597 | 1/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | CRHBP | P24387 | 2/20 | 0.40 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
| ▸ | FLT1 | P17948 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2461132 | 0.98 | MTNR1A (0.44) | MTNR1AITGB2ICAM1ITGALTYK2 | |
| Hydrochloric Acid SCHEMBL2462172 | 0.91 | KDM1A (0.39) | MTNR1AITGB2ICAM1ITGALTYK2 | |
| SCHEMBL507057 | 0.84 | TTBK1 (0.47) | MTNR1AKDM4ELMNAABCB1FLT1 | |
| SCHEMBL21571848 | 0.80 | ITGB2 (0.44) | MTNR1AITGB2ICAM1ITGALADRB1 | |
| SCHEMBL2504920 | 0.80 | ITGB2 (0.44) | MTNR1AITGB2ICAM1ITGALADRB1 | |
| SCHEMBL21571866 | 0.79 | MTNR1A (0.42) | MTNR1AITGB2ICAM1ITGALADRB1 | |
| SCHEMBL15650620 | 0.79 | MTNR1A (0.45) | MTNR1AITGB2ICAM1ITGAL | |
| SCHEMBL2961606 | 0.77 | MTNR1A (0.57) | MTNR1AKDM4EMRGPRX1ABCB1FLT1 | |
| SCHEMBL22421809 | 0.75 | MTNR1A (0.42) | MTNR1AMRGPRX1 | |
| SCHEMBL1150917 | 0.74 | PARP1 (0.47) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240024266-A1 | Therapeutic Agent or Prophylactic Agent for COVID-19 | HIROSHIMA UNIVERSITY (JP) | 2024-01-25 | — | — | US | disclosed |
| US-20240024266-A1 | Therapeutic Agent or Prophylactic Agent for COVID-19 | HIROSHIMA UNIVERSITY (JP) | 2024-01-25 | — | — | US | disclosed |
| WO-2023141511-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY (US) | 2023-07-27 | — | — | WO | disclosed |
| US-20230133581-A1 | Novel 3,5-Diaminobenzoic Acid Compound, and PIN1 Inhibitor and Therapeutic Agent for Inflammatory Diseases Using Same | HIROSHIMA UNIVERSITY (JP) | 2023-05-04 | — | — | US | disclosed |
| US-20230133581-A1 | Novel 3,5-Diaminobenzoic Acid Compound, and PIN1 Inhibitor and Therapeutic Agent for Inflammatory Diseases Using Same | HIROSHIMA UNIVERSITY (JP) | 2023-05-04 | — | — | US | disclosed |
| WO-2021213317-A1 | HPK1 INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 微境生物医药科技(上海)有限公司 (CN) | 2021-10-28 | — | — | WO | disclosed |
| EP-3756464-A1 | SUBSTITUTED OXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI | BASF SE (DE) | 2020-12-30 | — | — | EP | disclosed |
| EP-3151669-B1 | USE OF SUBSTITUTED OXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI | BASF SE (DE) | 2020-10-28 | — | — | EP | disclosed |
| US-20200283398-A1 | USE OF SUBSTITUTED OXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI | BASF SE (DE) | 2020-09-10 | — | — | US | disclosed |
| EP-3275867-B1 | PYRIDO-FUSED BICYCLIC COMPOUNDS AS URAT1 INHIBITORS FOR TREATING HYPERURICEMIA | SHANGHAI YINGLI PHARM CO LTD (CN) | 2020-06-10 | — | — | EP | disclosed |
| US-7566786-B2 | Quinoline derivatives as phosphodiesterase inhibitors | GLAXO GROUP LIMITED (GB) | 2009-07-28 | — | — | US | disclosed |
| CN-101400336-A | Novel flavoring agents, taste modifiers, tastants, taste enhancers, umami or sweeteners and/or enhancers and uses thereof | SENOMYX INC (US) | 2009-04-01 | — | — | CN | disclosed |
| EP-1944305-A1 | Quinoline derivatives as phosphodiesterase inhibitors | GLAXO GROUP LIMITED (GB) | 2008-07-16 | — | — | EP | disclosed |
| CN-101203142-A | Aromatic amides and ureas and their uses as sweet and/or delicate flavor modifiers, flavouring agents and taste enhancers | SENOMYX INC (US) | 2008-06-18 | — | — | CN | disclosed |
| EP-1633748-B1 | QUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LTD (GB) | 2008-03-05 | — | — | EP | disclosed |
| US-20070142373-A1 | Quinoline derivatives as phosphodiesterase inhibitors | GLAXO GROUP LIMITED (GB) | 2007-06-21 | — | — | US | disclosed |
| US-20070142373-A1 | Quinoline derivatives as phosphodiesterase inhibitors | GLAXO GROUP LIMITED (GB) | 2007-06-21 | — | — | US | disclosed |
| US-20070049570-A1 | Quinoline derivatives as phosphodiesterase inhibitors | DEAN ANTHONY W | 2007-03-01 | — | — | US | disclosed |
| US-20070049570-A1 | Quinoline derivatives as phosphodiesterase inhibitors | DEAN ANTHONY W | 2007-03-01 | — | — | US | disclosed |
| WO-2004103998-A1 | QUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133581-A1 | Novel 3,5-Diaminobenzoic Acid Compound, and PIN1 Inhibitor and Therapeutic Agent for Inflammatory Diseases Using Same | PIN1, DUSP15, FKBP1A | MTNR1A 2451/4885ITGB2 4759/4885ICAM1 2108/4885 |
| US-20240024266-A1 | Therapeutic Agent or Prophylactic Agent for COVID-19 | PIN1, ACE2, ACE | MTNR1A 2000/4885ITGB2 4849/4885ICAM1 2250/4885 |
| US-20070049570-A1 | Quinoline derivatives as phosphodiesterase inhibitors | PDE3B, PDE4B, PDE4A | MTNR1A 1694/4885ITGB2 4498/4885ICAM1 3437/4885 |
| US-20200283398-A1 | USE OF SUBSTITUTED OXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI | CYP51A1, DPM1, NOX1 | MTNR1A 2082/4885ITGB2 3564/4885ICAM1 3848/4885 |
| US-20070142373-A1 | Quinoline derivatives as phosphodiesterase inhibitors | PDE3B, PDE4B, PDE4A | MTNR1A 1694/4885ITGB2 4498/4885ICAM1 3437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.